Fitoterapia
September 1, 2023
Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al.
14 citations
Natural psychedelic compounds like psilocybin and DMT show promise as novel treatments for depression. This review explains how these substances produce therapeutic effects by interacting with various neurotransmission systems in the brain. It covers current antidepressant strategies and explores the unique mechanisms of natural psychedelics, including DMT, mescaline, ibogaine, and compounds from Amanita mushrooms. The authors describe how these agents may offer alternatives to conventional antidepressants by targeting different neural pathways.
Fitoterapia
January 1, 2010
Yong-Sheng Jin, Jing-Ling Du, Hai-Sheng Chen et al.
9 citations
From the stems of the plant Ervatamia yunnanensis, a new indole alkaloid named ervataine was isolated and its structure identified using spectroscopic analysis. Five other known alkaloids—ibogaine, coronaridine, heyneanine, voacangine hydroxyindolenine, and coronaridine hydroxyindolenine—were also found.
Fitoterapia
September 1, 2023
M E González-trujano, N Páez-martínez, F Krengel et al.
4 citations
An alkaloid extract from the root bark of the Mexican tree Tabernaemontana arborea contains several monoterpenoid indole alkaloids, including voacangine, ibogaine, vobasine, coronaridine, and ibogamine. In murine models, the extract produced dose- and receptor-dependent antidepressant-like effects at low doses (0.1 to 1 mg/kg) via 5-HT1A receptors and antinociceptive effects at higher doses (30 and 56.2 mg/kg) via opioid receptors, without impairing motor coordination, ambulatory activity, or memory. Electroencephalography showed central nervous system depressant activity at the highest doses. The alkaloid mixture may hold therapeutic value for pain relief and psychiatric conditions without neurotoxic effects at effective doses.
Fitoterapia
June 1, 2023
Caroline V L Moreira, Ana Luiza G Faria, Daiany P B Silva et al.
2 citations
A new compound called P-3l, an analogue of salvinorin A, reduces pain and anxiety-like behaviors in mice after oral administration at doses of 1, 3, 10, and 30 mg/kg. It lessened acetic acid-induced writhing, formalin-induced paw licking, hotplate responses, and aversion in elevated plus-maze, open field, and light-dark box tests. P-3l also boosted the effects of morphine and diazepam at low doses without causing changes in organ weight or blood parameters. The pain and anxiety relief were blocked by naloxone, naloxonazine, nor-binaltorphimine, and flumazenil, indicating involvement of opioid receptors and the benzodiazepine site. These findings suggest P-3l may have clinical potential for pain and anxiety treatment.